Pelvic Inflammatory Disease (PID) – CDC Detailed Fact Sheet

What is pelvic inflammatory disease?

Pelvic inflammatory disease (PID) is a clinical syndrome that results from the ascension of microorganisms from the cervix and vagina to the upper genital tract. PID is a serious complication of chlamydia and gonorrhea, two of the most common reportable infectious diseases and sexually transmitted diseases (STDs) in the US.

Women with PID may present with a variety of clinical signs and symptoms that range from unnoticeable or subtle and mild to severe. PID can go unrecognized by women and their health care providers when the symptoms are mild. Despite lack of symptoms, histologic evidence of endometritis has been demonstrated in women with subclinical PID.1 When present, signs and symptoms of PID are nonspecific, so other reproductive tract illnesses and diseases of both the urinary and the gastrointestinal tracts should be considered when evaluating a sexually active woman with lower abdominal pain. Pregnancy (including ectopic pregnancy) must also be excluded, as PID can occur concurrently with pregnancy.

When symptoms are present, the most common symptoms of PID are

  • Lower abdominal pain
  • Mild pelvic pain
  • Increased vaginal discharge
  • Irregular menstrual bleeding
  • Fever (>38° C)
  • Pain with intercourse
  • Painful and frequent urination
  • Abdominal tenderness
  • Pelvic organ tenderness
  • Uterine tenderness
  • Adnexal tenderness
  • Cervical motion tenderness
  • Inflammation

How do women get pelvic inflammatory disease?

Women develop PID when certain bacteria, such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), move upward from a woman’s vagina or cervix into her reproductive organs. PID can lead to infertility and permanent damage of a woman’s reproductive organs.

What causes pelvic inflammatory disease?

A number of different microorganisms can cause or contribute to PID. The sexually transmitted pathogens C. trachomatis and N. gonorrhoeae have been implicated in a third to half of PID cases.2-8 However, endogenous microorganisms, including gram positive and negative anaerobic organisms and aerobic/facultative gram positive and negative rods and cocci, found at high levels in women with bacterial vaginosis, also have been implicated in the pathogenesis of PID.9-11 Newer data suggest that Mycoplasma genitalium (Mgen) may also play a role in PID and may be associated with milder symptoms 4,12,13 although studies have failed to demonstrate a significant increase in PID following detection of Mgen in the lower genital tract.14-16 Because of the polymicrobial nature of PID, broad-spectrum regimens that provide adequate coverage of likely pathogens are recommended.7

What are the complications of pelvic inflammatory disease?

Complications of PID include

Tubo-ovarian abscess (TOA) is a serious short-term complication of PID that is characterized by an inflammatory mass involving the fallopian tube, ovary, and, occasionally, other adjacent pelvic organs. The microbiology of TOAs is similar to PID and the diagnosis necessitates initial hospital admission. Treatment includes broad-spectrum antibiotics with or without a drainage procedure, with surgery often reserved for patients with suspected rupture or who fail to respond to antibiotics. Women infected with human immunodeficiency virus (HIV) may be at higher risk for TOA. Mortality from PID is less than 1% and is usually secondary to rupture of a TOA or to ectopic pregnancy.

Recurrent episodes of PID and increased severity of tubal inflammation detected by laparoscopy are associated with greater risk of infertility following PID.17 However, even subclinical PID has been associated with infertility.1 This emphasizes the importance of following screening and treatment recommendations for chlamydia and gonorrhea to prevent PID when possible, and promptly and appropriately treating cases of PID that do occur.

How common is pelvic inflammatory disease in the United States?

PID is a frequent and important infection that occurs among women of reproductive age. Based on data from the National Health and Nutrition Examination Survey (NHANES) 2013-2014 cycle, the estimated prevalence of self-reported lifetime PID was 4.4% in sexually experienced women of reproductive age (18–44 years).18 This equates to an estimated 2.5 million women in the United States with a reported lifetime history of PID diagnosis. The prevalence was highest in women at increased risk, such as those with previous sexually transmitted infections (STIs).18

The significant burden of disease attributed to PID comes predominantly from the long-term reproductive sequelae of tubal infection: tubal factor infertility, ectopic pregnancy, and pelvic adhesions, which can lead to chronic pelvic pain. Our knowledge of the longitudinal outcomes for affected women who experience PID is primarily derived from data published using a Scandinavian cohort of inpatients diagnosed with PID.19  Data from this study indicated that those women with PID were more likely to have ectopic pregnancy (6 times increased rate), tubal factor infertility (ranging from 8% after the first episode to as high as 40% after three episodes) and chronic pelvic pain (18% following one episode).

Is the number of women in the United States being diagnosed with pelvic inflammatory disease increasing?

Generally there have been several studies published suggesting overall declines in PID diagnosis in both hospital and ambulatory settings,20-22 however some of these same studies have noted a possible increase in PID starting in 2015.23 While no single explanation exists for the previous declining trend, some have suggested that changes in sexually transmitted disease rates, increases in chlamydia screening coverage, availability of antimicrobial therapies that increase adherence to treatment, and more sensitive diagnostic technologies, could be impacting PID rates.24

How is pelvic inflammatory disease diagnosed?

The wide variation in symptoms and signs associated with PID can make diagnosis challenging. No single historical, physical, or laboratory finding is both sensitive and specific for the diagnosis of PID. Clinicians should therefore maintain a low threshold for the diagnosis of PID, particularly in young, sexually active women.

Criteria have been developed for the diagnosis of PID.7

Presumptive treatment for PID should be initiated in sexually active young women and other women at risk for STDs if they are experiencing pelvic or lower abdominal pain, if no cause for the illness other than PID can be identified, and if one or more of the following minimum clinical criteria are present on pelvic examination:

  • cervical motion tenderness
  • uterine tenderness
  • adnexal tenderness.

The requirement that all three minimum criteria be present before the initiation of empiric treatment could result in insufficient sensitivity for the diagnosis of PID. After deciding whether to initiate empiric treatment, clinicians should also consider the risk profile for STDs.

More elaborate diagnostic evaluation frequently is needed because incorrect diagnosis and management of PID might cause unnecessary morbidity. For example, the presence of signs of lower-genital–tract inflammation (predominance of leukocytes in vaginal secretions, cervical exudates, or cervical friability), in addition to one of the three minimum criteria, increases the specificity of the diagnosis. One or more of the following additional criteria can be used to enhance the specificity of the minimum clinical criteria and support a diagnosis of PID:

  • oral temperature >101°F (>38.3°C);
  • abnormal cervical mucopurulent discharge or cervical friability;
  • presence of abundant numbers of WBC on saline microscopy of vaginal fluid;
  • elevated erythrocyte sedimentation rate;
  • elevated C-reactive protein; and
  • laboratory documentation of cervical infection with N. gonorrhoeae or C. trachomatis.

Most women with PID have either mucopurulent cervical discharge or evidence of WBCs on a microscopic evaluation of a saline preparation of vaginal fluid (i.e., wet prep). If the cervical discharge appears normal and no WBCs are observed on the wet prep of vaginal fluid, the diagnosis of PID is unlikely, and alternative causes of pain should be considered. A wet prep of vaginal fluid also can detect the presence of concomitant infections (e.g., BV and trichomoniasis).

The most specific criteria for diagnosing PID include:

  • endometrial biopsy with histopathologic evidence of endometritis;
  • transvaginal sonography or magnetic resonance imaging techniques showing thickened, fluid-filled tubes with or without free pelvic fluid or tubo-ovarian complex, or Doppler studies suggesting pelvic infection (e.g., tubal hyperemia); or
  • laparoscopic findings consistent with PID.

A diagnostic evaluation that includes some of these more extensive procedures might be warranted in some cases. Endometrial biopsy is warranted in women undergoing laparoscopy who do not have visual evidence of salpingitis, because endometritis is the only sign of PID for some women.

A test for human immunodeficiency virus (HIV) is also recommended. A pregnancy test should always be performed to exclude ectopic pregnancy and because PID can occur concurrently with pregnancy. When the diagnosis of PID is questionable, or when the illness is severe or not responding to therapy, further investigation may be warranted using other invasive procedures (endometrial biopsy, transvaginal ultrasonography, magnetic resonance imaging, or laparoscopy).

How is pelvic inflammatory disease treated?

PID is treated with broad spectrum antibiotics to cover likely pathogens. Several types of antibiotics can cure PID. Antibiotic treatment does not, however, reverse any scarring that has already been caused by the infection. For this reason, it is critical that a woman receive care immediately if she has pelvic pain or other symptoms of PID. Prompt antibiotic treatment could prevent severe damage to the reproductive organs.

Recommended treatment regimens can be found in the 2021 STI Treatment Guidelines7 Health care providers should emphasize to their patients that although their symptoms may go away before the infection is cured, they should finish taking all of the prescribed medicine. Additionally, a woman’s sex partner(s) should be treated to decrease the risk of re-infection, even if the partner(s) has no symptoms. Although sex partners may have no symptoms, they may still be infected with the organisms that can cause PID.

In certain cases, clinicians may recommend hospitalization to treat PID. This decision should be based on the judgment of the health care provider and the use of suggested criteria found in the 2021 STI Treatment Guidelines.7 If a woman’s symptoms continue, or if an abscess does not resolve, surgery may be needed.

How can clinicians manage PID?

A critical component to management is short-term follow-up, especially in the adolescent population. Since many adolescent women rely on outpatient services for the evaluation and treatment of STD symptoms, the need for a low diagnostic and management threshold for PID is even more critical, as the likelihood for additional follow-up care is low.

What should a patient do after being diagnosed with pelvic inflammatory disease?

A patient should abstain from sexual intercourse until she and her partner(s) have completed treatment. Female latex condoms are also an option if a woman prefers them or if her male partner chooses not to use male condoms. Women who are told they have an STD and are treated for it should notify all of their recent sex partners so they can see a health care provider and be evaluated for STDs.

The diagnosis of PID provides an opportunity to educate adolescent and young women about prevention of STDs, including abstinence, consistent use of barrier methods of protection, immunization, partner evaluation and treatment, and the importance of receiving periodic screening for STDs and HIV.

How can pelvic inflammatory disease be prevented?

Latex condoms may reduce the risk of PID by preventing STDs. Since STDs play a major role in PID, screening of women at risk for infection and treatment of infected women and their sex partners can help to minimize the risk of PID. Screening of young sexually active women for chlamydia has been shown to decrease the incidence of PID.28, 29

The United States Preventive Services Task Force recommends annual chlamydia and gonorrhea screening in women younger than 25 years25 and CDC recommends that providers screen the following populations for chlamydia and gonorrhea: all sexually active women younger than 25 years, as well as older women with risk factors such as new or multiple sex partners, or a sex partner who has a sexually transmitted infection.

What is the economic burden of pelvic inflammatory disease in the United States?

A decline in incidence of PID is also reflected in the most recent cost estimates of PID and its sequelae. Direct medical expenditures for PID and its sequelae were estimated at $1.88 billion in 1998,30 compared to approximately $2.7 billion estimated in 1990.31 Based on NHANES 2013–2014 data, an estimated 2.5 million women aged 18–44 years in the United States reported a lifetime history of PID diagnosis,18 with each case of PID having an estimated cost of $3,202 .32


  1. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, and Sweet RL. Subclinical pelvic inflammatory disease and infertility. Obstet & Gyn, 2012; 120:37-43.
  2. Haggerty CL, Ness RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. Expert Rev Anti Infect Ther. 2006;4:235-47.
  3. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002;186:929-37.
  4. Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic Inflammatory disease. Clin Infect Dis 2020:ciaa101.
  5. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med 2012;30:1114-7.
  6. Goller JL, De Livera AM, Fairley CK, et al. Population attributable fraction of pelvic inflammatory disease associated with chlamydia and gonorrhoea: a cross-sectional analysis of Australian sexual health clinic data. Sexually transmitted infections 2016;92:525-31.
  7. Workowski, KA, Bachmann, LH, Chang, PA, et. al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70(No. 4): 1-187.
  8. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. American journal of obstetrics and gynecology 2002;186:929-37.
  9. Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecolo 1996;175;435-41.
  10. Eschenbach DA, Buchanan TM, Pollock HM, Forsyth PS, Alexander ER, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N. Engl J Med. 1975;293:166-171.
  11. Hebb JK, Cohen CR, Astete SG, Bukusi EA, Totten PA. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. The Journal of infectious diseases 2004;190:2109-20.
  12. Simms I, Eastick K, Mallinson H, et al. Association between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol 2003;56:616.618.
  13. Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect. 2005;81:463-466.
  14. Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the “New Chlamydia?” A community-based prospective cohort study. Clin Infect Dis 2010;51:1160–6.
  15. Oliphant J, Azariah S. Pelvic inflammatory disease associated with Chlamydia trachomatis but not Mycoplasma genitalium in New Zealand. Sexual health 2016;13:43-8.
  16. Hay PE, Kerry SR, Normansell R, et al. Which sexually active young female students are most at risk of pelvic inflammatory disease? A prospective study. Sexually transmitted infections 2016;92:63-6.
  17. Westrom L, Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880-892.
  18. Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R. Prevalence of Pelvic Inflammatory Disease in Sexually Experienced Women of Reproductive Age — United States, 2013–2014. MMWR Morb Mortal Wkly Rep 2017;66:80–83.
  19. Westrom L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. Sex Trans Dis. 1992;19(4):185-192.
  20. Berman SM, Holmes KK. Sexually Transmitted Diseases, ed. S.P. Holmes KK, Mardh PA, et al., 1999, New York: McGraw-Hill.
  21. Bohm MK, Newman L, Satterwhite CL, et al. Pelvic inflammatory disease among privately insured women, United States, 2001–2005. Sex Transm Dis. 2010;37:131–136.
  22. Sutton MY, Sternberg M, Zaidi A, et al. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. Sex Trans Dis. 2005;32:778-84.
  23. Kreisel K. The epidemiology of pelvic inflammatory disease in the United States, 2006–2016. 2020 STD Prevention Conference; September 15, 2020; Atlanta, Georgia; 2020.
  24. Owusu-Edusei K Jr, Bohm MK, Chesson HW, et al. Chlamydia screening and pelvic inflammatory disease: insights from exploratory time-series analyses. Am J Prev Med. 2010;38:652–657.
  25. U.S. Preventive Services Task Force. The Guide to Clinical Preventive Services 2014. U.S. Department of Health and Human Services; 2014.
  26. Paavonen J, Westrom L, and Eschenbach D in Sexually Transmitted Diseases, Holmes K, et al editors, McGraw Hill Medical, 2008.
  27. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013–9; Viberga I, Odlind V, Lazdane G, et al. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol 2005;13:183–90.
  28. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334:1362–1366.
  29. Oakeschott, P, Kerry S, Aghaizu A, et al. Randomized controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340:c1642.
  30. Rein, D B. Kassler, W J. Irwin, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet & Gynecol. 2000;95:397-402.
  31. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA. 1991;266:2565–9.
  32. Owusu-Edusei K, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013;40:197–201.
Need Help Printing this Page?

Consider adjusting the scale or “shrink to fit” in your browser settings, or consult the printing instructions applicable to your browser. Alternatively, consider using the STD facts brochures or ordering materials through CDC-INFO on Demand (please note: stock is limited).
Chromeexternal icon | Safariexternal icon | Edgeexternal icon | Firefoxexternal icon | IEexternal icon

Additional Information

In English, en Español

CDC National Prevention Information Network (NPIN)

American Sexual Health Association (ASHA)external icon

Health care providers with STD consultation requests can contact the STD Clinical Consultation Network (STDCCN)external icon.